Autopsy report · NCT01740388

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

“Strategic business decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 9 months before it stopped.
• 136 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Bausch & Lomb Incorporated

Sponsor type

Industry

Conditions

Bacterial Conjunctivitis

Interventions

Besifloxacin; Vehicle

Participants

136

Sites

1

Countries

United States

Trials that died the same way

• Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test
  “Business Strategic Decision” (99% match in meaning)
• CD8 Minibody Repeatability Study
  “Strategic decision” (91% match in meaning)
• Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
  “Strategic corporate decision” (91% match in meaning)
• A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
  “Company's strategic decision” (89% match in meaning)
• A Study of RBI-4000 in Healthy Participants
  “Strategic business decision (not related to safety, efficacy, or quality)” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.